Analytical validation of a circulating tumor DNA assay using PhasED-Seq technology for detecting residual disease in B-cell malignancies
Oncotarget · 09.05.2025 · 16 (1) · 329-336
DOI: 10.18632/oncotarget.28719 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Oncotarget, online erschienen am 09.05.2025. Verfasst von Nina Klimova und 4 weiteren Autor:innen. Beteiligte Einrichtung: Foresight Diagnostics, Boulder, CO 80301, USA. Hauptthemen laut MEDLINE: Neoplasm, Residual, Circulating Tumor DNA, Lymphoma, Large B-Cell, Diffuse, High-Throughput Nucleotide Sequencing. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Foresight Diagnostics, Boulder, CO 80301, USA.
Zitieren
APA
Klimova, N., Close, S., Kurtz, D. M., Hockett, R. D., & Hyland, L. (2025). Analytical validation of a circulating tumor DNA assay using PhasED-Seq technology for detecting residual disease in B-cell malignancies. Oncotarget, 16(1), 329-336. https://doi.org/10.18632/oncotarget.28719
Vancouver
Klimova N, Close S, Kurtz DM, Hockett RD, Hyland L. Analytical validation of a circulating tumor DNA assay using PhasED-Seq technology for detecting residual disease in B-cell malignancies. Oncotarget. 2025;16(1):329-336. doi:10.18632/oncotarget.28719
BibTeX
@article{Klimova2025,
author = {Klimova, Nina and Close, Sandra and Kurtz, David M and Hockett, Richard D and Hyland, Laura},
title = {Analytical validation of a circulating tumor DNA assay using PhasED-Seq technology for detecting residual disease in B-cell malignancies},
journal = {Oncotarget},
year = {2025},
volume = {16},
number = {1},
pages = {329--336},
doi = {10.18632/oncotarget.28719}
}
EUVIMED